View Older Stories View More Recent Stories
-
Zymeworks to Acquire Theravance Biopharma, Inc.
-
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
-
Saks Global Successfully Emerges as Exemplar Luxury Group Offering Unrivaled Customer Experiences Across Neiman Marcus, Saks Fifth Avenue and Bergdorf Goodman
-
Trump clean energy tax credit cutoff drives project rush as prices set to soar
-
Form D/A Lazard Japanese Strategi
-
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May
-
Form S-8 Lazard, Inc.
-
Thoreau to Make Strategic Growth Investment in Ensemble
-
YUM China to buy Pizza Hut brand in mainland China for $1.2B
-
Yum China to Acquire Ownership of the Pizza Hut Brand in Mainland China
-
OLIN and HUNTSMAN agree to all-stock merger valued at $12.5B
-
Searles Valley Minerals Initiates Court-Supervised Sale of its Critical Minerals Platform
-
Banqup Group Announces Strategic Simplification Plan and Launch of Process to Explore Strategic Alternatives
-
Lazard bids to replace Centerview as Venezuela financial adviser, source says
-
Form D/A Lazard International
-
Chiesi Group completes KalVista acquisition for $27 per share
-
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
-
Developing world's 'complex' debt could raise costs, stall restructurings, Lazard says
-
Motive Partners Invests in Mobius to Build the Future of Pension and Wealth Investment Infrastructure
-
/C O R R E C T I O N -- THE GOOD DOG FOUNDATION/
-
NY Business Leaders Come Out in Force to Support Global Hope & Healing Via the Human-Animal Bond
-
Lazard reports May assets under management at $284.8 billion
-
Lazard Reports May 2026 Assets Under Management
-
Minerva Launches AI Platform for Consumer Marketing with $20M from The General Partnership, 8VC, Lingotto Innovation, Topology Ventures and NBA Investments, Alongside OpenAI Collaboration
-
UBS Reiterates Neutral Rating on Lazard (LAZ) Ahead of May AUM Data
-
AllerGene AI Therapeutics Appoints Biotech Industry Veteran Gad Berdugo to Board of Directors
-
Incyte to acquire Vega Therapeutics for $1.25 billion upfront
-
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
-
Saks Global Secures Court Approval of Plan of Reorganization, Paving the Way for Emergence
-
Form N-MFP3 LAZARD FUNDS INC For: May 31
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Jarrard Michelle
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Harrison Peter
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Alper Andrew M
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Achleitner Ann-Kristin
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Knobloch Iris
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Shevelenko Dmitry
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: SCHULMAN DANIEL H
-
Form 4 Lazard, Inc. For: Jun 01 Filed by: Howe Stephen R. Jr.
-
Ella Curren joins UBS as Financial Advisor in New York City
-
ACA Group Appoints Trey Loughran as Chief Executive Officer
-
Athene names Matthew Michelini president of holding company
-
Athene Announces Key Leadership Appointment
-
Waldencast agrees to sell Obagi Medical to Bridgepoint for up to $460 million
-
Waldencast Announces Sale of Obagi Medical to Bridgepoint
-
€900M European Consulting and Technology Leader Magellan Expands Into UK Market Following Strategic Acquisition of Transport and Mobility Giant MeTS
-
BMO hires UBS banker to lead US M&A team, memo shows
-
Form NPORT-P LAZARD FUNDS INC For: Mar 31
-
Form NPORT-P LAZARD FUNDS INC For: Mar 31
-
Form NPORT-P LAZARD FUNDS INC For: Mar 31
-
Form NPORT-P LAZARD FUNDS INC For: Mar 31
